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Manipulation of Human Immunodeficiency Virus restriction factors: RPRD2, SERINC3 
and SERINC5 
Olumuyiwa Ariyo 
Abstract 
Background: There is a need for a newer approach to tackle human immunodeficiency virus (HIV) due to 
limitations of the current antiretrovirals, innate cell restriction factors offer such opportunity. This study seeks to 
characterise three novel HIV restriction factors and explore their therapeutic potentials. 
 
Methods: Jurkat cell line was treated with polyinosinic-polycytidylic acid (poly I:C), a toll-like receptor-3 agonist 
(TLR3), at different concentrations (5 µg/ml, 10 µg/ml, 20 µg/ml) and (4 µg/ml, 8 µg/ml, 12 
µg/ml) and untreated controls. Its effects on cellular proliferation were observed over many hours. A 
bioinformatic search of Regulation of nuclear pre-mRNA domain-containing 2 (RPRD2) and Serine incorporator 
3 and 5 (SERINC3 and SERINC5) were conducted to predict for nuclear localisation signal (NLS) and potential 
ubiquitination and Sumoylation sites in the proteins using online NLS Mapper, UbPred and GPS-SUMO tools 
respectively. Small interference RNA (siRNA) transfection of Jurkat cell line was done to knockdown 
karyopherin alpha 2 (KPNA2) using Lipofectamine 3000. Western blot analysis was done to assess transfection 
efficiency. 
 
Results: Jurkat cells treated with 5 µg/ml, 10 µg/ml and 20 µg/ml proliferated more than the control while those 
treated with 4 µg/ml, 8 µg/ml and 12 µg/ml proliferated less with statistical significance between the untreated 
and 4 µg/ml concentration at 72 hours (p = 0.021).RPRD2 was the only protein that has NLS 
(RDPFHSLKRPRPPFARGPPFFAPKRPFFP)at position 1430 with a score of 9.8. RPRD2 has a site predicted each for 
SUMO interaction and sumoylation consensus (p = 0.022), SERINC3 had six sites for SUMO interactions and 2 for 
sumoylation non-consensus, all with no statistical significance and SERINC5 has a significant SUMO interaction 
site at position 44-48 (p = 0.049). The predicted ubiquitination sites for RPRD2 were 44 (ten with high, 27 with 
medium and seven with low confidence respectively), SERINC3 had four sites (two with medium and low 
confidence each) and SERINC5 had three (one with high, medium and low confidence each). The KPNA2 
knockdown was not successful. 
 
Conclusion: HIV restriction factors present a potential therapeutic target; adequate characterisation of these 
proteins is important towards fashioning drugs in this regard.  
 
Keywords: Toll-like receptor 3, Polyinosinic-polycytidylic acid (poly I:C), Nuclear localisation signal, Sumoylation, 
Ubiquitination, Karyopherin alpha 2 (KPNA2)  
 
Introduction 
The war against human immunodeficiency virus (HIV) 
is not yet over though some battles have been won 
with the help of combination antiretroviral therapy 
that has significantly reduced its morbidity and 
mortality [1–3]. However, nearly a million lives are still 
lost annually to HIV infection [1, 4]; this has 
necessitated the need to fashion new weapons to 
fight the disease [5, 6]. One of the areas of ongoing 
research is understanding how the  immune cells can 
be able to control the viral infection [7, 8], prominent 
in this regard are proteins that have been reported to 
restrict HIV infection and are generally called HIV 
restriction factors [9–11]. Pathogen-associated 
molecular patterns (PAMPs) that are common to 
almost all organism activates cellular pattern 
recognition receptors (PRRs) of which toll-like 
receptors (TLRs) family is a group [12, 13], the 
activation of TLR3 has been reported to cause 
interferon-mediated expression of restriction factors 
[14]. TLR3 has been shown to recognise different forms 
of double-stranded RNA (dsRNA), a viral replication 
intermediate, giving way for the use of synthetic 
analogue of dsRNA to be employed in researches 
[15, 16]. A common example that has been used is 
poly I:C [17, 18]. For instance it leads to 
apolipoprotein B messenger RNA (mRNA)-editing 
enzyme catalytic polypeptide-like 3G(APOBEC3G) 
and tetherin upregulation in macrophages [19, 
20].However, the virus has accessory proteins that 
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counter the action of the restriction factors. The 
accessory proteins in HIV-1 are Vif, Vpr, Vpu, Nef (and 
Vpx in HIV-2) [21–23]. Many HIV restriction factors 
have been discovered, well-known example include 
(APOBEC3) family of protein especially APOBEC3G, 
tripartite-motif-containing 5α (TRIM5α), and 
tetherin/bone marrow stromal cell antigen 2 (BST2) 
[24–27].  The new ones include  Zinc-finger antiviral 
protein (ZAP), Serine incorporator 3 and 5 (SERINC3/5) 
and RPRD2 (also called RNA-associated early-stage 
antiviral factor, REAF) [28–30]. The functions of 
restriction factors can be modified by post-
translational modifications (PTM) such as the addition 
of ubiquitin and small ubiquitin-like  modifiers (SUMO) 
proteins called ubiquitination and sumoylation 
respectively in addition to their nucleocytoplasmic 
transport [31–34]. Importin alpha such as karyopherin 
alpha 2 (KPNA2) has been documented to be 
involved in the latter [35]. Some restriction factors 
have been well characterised while interest is 
increasing about the novel one such as RPRD2, 
SERINC3 and SERINC5 [29, 30, 34, 36], as this could be 
an avenue to develop new therapy at tackling 
HIV[37–39].Therefore, this study seeks to undertake 
the following: (I) study the effect of poly I:C on cellular 
proliferation (II) prediction of NLS, ubiquitination and 
sumoylation sites, of RPRD2, SERINC3 and SERINC5 (III) 
Knockdown of KPNA2 protein. 
 
Materials and methods 
Cell Culture 
Jurkat cell line (E6-1) was cultured in RPMI growth 
medium (Lonza) containing 10% foetal bovine serum 
(FBS, ThermoFisher Scientific), 1% penicillin (Sigma) and 
1% streptomycin solution (Sigma) in a T 25 cm3 flask. 
The cell culture was incubated at 370C and humidified 
air with 5% CO2. The cells passaging was done at 3 to 
4 days intervals. 
Poly I:C treatment 
A sterile 24-well plate was plated in duplicate with 
1×105 cells/well in RPMI containing 10% FBS and 
penicillin-streptomycin. Cells were then treated with 
high molecular weight (HMW) poly I:C (InvivoGen) at 
different concentrations (5 µg/ml, 10 µg/ml and 20 
µg/ml). Untreated cells in duplicate wells served as a 
control. The plate was incubated at 370C and 
humidified air with 5% CO2. The total viable cells were 
counted at 72 hours, 120 hours, and 168 hours by the 
haemacytometer method using 0.4% trypan blue stain 
(Sigma). In another instance, the plating of a sterile 24-
well plate was made in duplicate with 2×105cells/well 
in RPMI containing 10% FCS and penicillin-
streptomycin. The cells were treated with HMW poly 
I:C at different concentrations (4 µg/ml, 8µg/ml and 12 
µg/ml). There was a negative control also. The plate 
was incubated at 370C and 5% C02 humidified air. The 
total viable cells were counted at 24 hours, 48 hours, 
72 hours and 96 hours by the haemacytometer 
method using 0.4% trypan blue stain (Sigma). 
Bioinformatics resources 
Three novel HIV restriction factors were selected: 
RPRD2, SERINC3 and SERINC5. The following searches 
were performed on each: prediction of NLS, potential 
ubiquitination and sumoylation sites. The FASTA format 
(text-based representation of peptide sequence) of 
each protein was accessed from 
https//www.uniport.org [40–43], figure 1.Classical NLS 
(cNLS) Mapper was used for the prediction of the NLS 
with the cut-off set at 5.0 and within the terminal 60-
amino-acid region [44]. UbPred was used for the 
prediction of the potential ubiquitination sites [45], 
while group-based prediction system, GPS-SUMO was 
used for the prediction of the potential sumoylation 
sites [46]. High performance determined the choice of 
the tools selected [47, 48]. The threshold for the GPS-
SUMO was set at medium for the sumoylation 
(sensitivity 67.93%, specificity 90.00%) and SUMO 
interaction (sensitivity 65.96%, specificity 90.03%, 
supplementary table 1. 
siRNA transfection 
Plating of a sterile 24-well plate was made with 2×105 
cells/well. Lipofectamine 3000 reagent (ThermoFisher 
Scientific,), 0.75µl and 1.5µl were diluted in 25µl Opti-
MEM medium each (Gibco) and mixed. 1 µg of 
KPNA2-specific Small interfering RNA (10 µM, 
ThermoFisher Scientific) 1µg was diluted in 50 µl of Opti-
MEM medium (Gibco), this was divided equally and 
mixed with the diluted Lipofectamine 3000 reagents 
and the complex was incubated for 30 minutes at 
room temperature. The complex reagents were 
added to a well of cells each and untreated control 
was also set up. The plate was incubated at 37oC with 
5% CO2 humidified air for 5 days after which the cells 
were harvested. Western blot was used to confirm 
transfection efficiency. 
Western blot 
The harvested cells were lysed in RIPA buffer mixed 
with protease inhibitor cocktail (ThermoFisher 
Scientific) on ice-cold, LDS sample buffer (Novex) and 
sample reducing agent (Novex) was added to aid cell 
lysis. The cells were also frozen at -80o C for 60 seconds 
and thawed to aid cell lysis further. The protein 
concentration was determined with the BCA protein 
assay kit (ThermoFisher) following the manufacturer’s 
guide. Heat blocking was done at 85o C for    
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Figure 1 FASTA format of amino acids for HIV restriction factors. (a)RPRD2 sequence with sequence identifier at the 
beginning (b) SERINC3 sequence with sequence identifier at the beginning (c) SERINC5 sequence with sequence 
identifier at the beginning. In the FASTA format, amino acids are represented with single-lettered code and start with 
a single-line description. However, they are presented in two lines here in other to make the sequences fit into the 
available space. 
 
a 
b 
c 
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10 minutes to denature the proteins. The extracted 
protein (25µg) was separated by sodium dodecyl sulfate, 
SDS (Novex) polyacrylamide gel electrophoresis, PAGEs 
(precast, ThermoFisher Scientific) at 200 Volts for 1 hour 30 
minutes. The separated proteins were transferred to a 
nitrocellulose membrane using the iBlot2 Dry Blotting 
System at 25 Volts for 6 minutes. The membrane was 
blocked with 5% milk in TBS (50 mM Tris-HCl, pH 7.6, 150mM 
NaCl) for 30 minutes at room temperature. Then the 
membrane was incubated with rabbit anti-KPNA2 
primary antibody (Abcam), 1:1000 dilution in 5% milk in 
TBS-T (50 mM Tris-Cl, pH 7.6, 150mM NaCl, containing 0.1% 
Tween-20) overnight at 40C. The membrane was then 
washed in TBS three times before it was incubated in goat 
anti-rabbit Ig-linked horseradish peroxidase (HRP) 
secondary antibody (Abcam), 1: 5,000 dilution in 5% milk 
in TBS-T for 1 hour. Anti-LAC antibody (Abcam), 1: 2,500 
dilution served as a control. The membrane was washed 
finally three times and West femto chemiluminescent 
substrate (ThermoFisher Scientific) was added and 
incubated for 5 minutes in the dark. Chemiluminescence 
imaging (Gensys) for band detection was done.  
Statistical analysis 
Data for the poly I:C treatment were expressed as the 
mean ± standard deviation of duplicate wells. A 
comparison was made between the mean of the treated 
versus control and statistical significance was assessed by 
the Student`s t-test using SPSS (version 25, IBM). Statistical 
significance was set at p < 0.05 
Results 
Poly I:C treatment 
Jurkat cells were treated with poly I:C at different 
concentrations versus untreated control. In figure 2a, the 
proliferation of the treated cells was more than that of the 
untreated control from 72 hours through 168 hours. 
However, this was not statistically significant. In figure 2b, 
the proliferation of the untreated Jurkat cells was 
generally more than that of those treated with poly I:C up 
till 72 hours (except with 12 µg/ml concentration at 72 
hours), before it fell below that of others at 96 hours. There 
was a statistically significant difference in the growth of 
the untreated cells compared with that of the cells 
treated cells with 4 µg/ml at 72 hours (p = 0.021) with 
proliferation being more in the untreated cells. This gives 
a contrasting finding on the effect of poly I:C on the 
cellular proliferation between the two sets of poly I:C 
concentrations. 
Nuclear localisation signal prediction 
The NLS signal was seen in RPRD2 at position 1430 
with an NLS score of 9.8. There was no NLS seen for 
SERINC3 and SERINC5 at the cut-off of 5.0 and 
within the terminal 60-amino-acids region used in 
this analysis. However, when the cut-off was set at 
the lowest value of 2.0 and within the entire region, 
positions for NLS were detected in SERINC3 and 
SERINC5 although the values were low, 
supplementary tables 5 and 6. 
Sumoylation prediction 
Many SUMO substrates contain tetrapeptide 
represented by ΨK×D/E (Ψ is hydrophobic residue, K is 
lysine, that is conjugated to the SUMO, × is any amino 
acid and D/E represent acidic residue. This conserved 
tetrapeptide is termed the SUMO consensus motif 
(SCM). Enzymatic covalent binding of SUMO to 
proteins involves Ubc9 enzyme. SUMO interacting 
motif (SIM) involves the non-covalent interaction of 
SUMO with proteins [47, 49, 50]. GPS-SUMO showed 
that when the threshold was set at medium, there was 
a position of statistical significant sumoylation 
consensus predicted for RPRD at 658 (p = 0.022) and 
one SUMO interaction site at position 383-387 and has 
p-value that approached statistical significance 
(0.056), figure 3a. For SERINC3, there were six positions 
predicted for SUMO interaction and two sumoylation 
non-consensus sites. There was none that was 
statistically significant. The closet to significance was 
SUMO interaction at position 177-181 (p =0.07) and 
position 246-250 (p =0.072) figure 3b. SERINC5 has a 
statistically significant SUMO interaction at position 44-
48 (p=0.049) figure 3c. 
Ubiquitination sites prediction 
Ubiquitination occurs at lysine residue denoted by 
(K)[43, 51].The predicted potential ubiquitination sites 
for RPRD2 was 44. There were ten residues with high 
confidence, 27 with medium confidence and seven 
with low confidence, figure 4a. For SERINC3 there were 
2 predicted sites each with medium and low 
confidence (figure 4b) while SERINC5 had one site 
each predicted for ubiquitination with high, medium 
and low confidence, figure 4c. The prediction 
confidence is based on the score range shown in 
figure 4d. The sensitivity and specificity of the 
corresponding range of scores are also stated. 
Western blot
  
The western blot showed that KPNA2 was present in both 
the siRNA treated cells and the control (band 58 kDa). 
Detection of Lamin A/C(LAC) served as a control 
(between bands 65- 70 kDa, supplementary figure 6. 
Therefore, the siRNA transfection to knockdown KPNA2 
was not successful. 
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Figure 2 The effects of poly I:C on Jurkat cell proliferation. (a)Jurkat cells treated with different concentrations of poly I:C (5 
µg/ml, 10 µg/ml and 20 µg/ml) versus untreated control. The cells were incubated at 370C and total viable cells were counted 
at 72 hours, 120 hours, 168 hours. (b)Jurkat cells treated with different concentrations of poly I:C (4 µg/ml, 8 µg/ml and 12 
µg/ml) versus untreated control. The cells were incubated at 370C and total viable cells were counted at 24 hours, 48 hours, 
72 hours and 96 hours. The results were expressed as mean ± SD of duplicate wells.  P = 0.021 
 
Table 1 Predicted bipartite NLS of RPRD2 
Position Sequence Score 
1430 RDPFHSLKRPRPPFARGPPFAPKRPFFP 9.8 
 
The predicted NLS of RPRD2 showing the position, sequence and score with the cut-off set at 5.0 and within the terminal 60-
amino-acids region of the protein. 
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Figure 3 Prediction results of sumoylation sites and SUMO interaction at a medium threshold. (a) RPRD2 with a SUMO interaction 
and sumoylation consensus each. (b) SERINC3 with six SUMO interaction sites and two sumoylation non-consensus. (c) SERINC5 
with a SUMO interaction site 
 The modified position, modified peptide, predicted scores, prediction cut-off, and regulation type are presented. P < 0.05 is 
significant 
 
 
Discussion 
Toll-like receptors recognise and respond to PAMPs 
leading to intracellular signal pathways activation, this 
process is important in the immune response to 
pathogens [12, 13]. There are 11 known TLRs, TLR-3 is 
involved in the key process of the immune response to 
viruses by the recognition of dsRNA (a common viral 
replication intermediate molecule) [12, 15]. The 
development of synthetic dsRNA analogue affords the 
opportunity to study the effect of TLR-3 activation in 
cellular processes.  poly I:C is a dsRNA analogue that has 
been employed in this regard [17]. In this study HMW poly 
I:C was used in preference to low molecular weight 
counterpart (LMW) as the former has been reported to 
have higher activation efficiency than the latter [52]. 
Jurkat cells were treated with different concentrations of 
HMW poly I:C and its effects on the proliferation of the 
cells were observed. In figure 2a, the proliferation of cells 
that were treated with HMW poly I:C was more than that 
of the control up to 168 hours, although this difference 
was not statistically significant. In figure 2b however, the 
effect of HMW poly I:C on Jurkat cell proliferation was 
different even though the concentrations used in both 
instances were similar. Overall, there was less proliferation 
of the treated cells up to 72 hours before a reduction in 
the growth of the control below that of others at 96 hours. 
A significant difference was noted at 72 hours between 
the control and 4 µg/ml concentration of poly I:C with 
more proliferation in the untreated cells. The effects of 
poly I:C on cell proliferation in the two instances in figure 
2 are contrasting. The effect seen in figure 2b is similar to 
some extent with what has been reported in other studies 
that documented that poly I:C is anti-proliferative [53–56]. 
This was reported in different cell lines and human 
macrophages. There was associated inhibition of HIV 
replication following the treatment of cells with poly I:C 
[14, 18, 19, 52]. One of the mechanisms underlying these 
has been documented to be related to the anti-viral 
response via the activation of intracellular signals 
mediated by interferons leading to the expression of 
restriction factors such as APOBEC3G and tetherin [14, 18, 
19, 52, 57].
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Figure 4 Ubiquitination of RPRD2, SERINC3 and SERINC5. (a) RPRD2 has 44 ubiquitination sites, seven sites with low confidence, 
27 sites with medium confidence and ten sites with high confidence. (b) SERINC3 ubiquitination sites, two sites with low 
confidence and two sites with medium confidence. (c) SERINC5 ubiquitination, one site each with low, medium and high 
confidence. (d) Label showing the range of scores with classification into low (green), medium(blue) and high (red) 
confidence of ubiquitination. The sensitivity and specificity of each are shown. Ub- ubiquitinated 
 
 
Therefore, TLR3 agonists could be developed as a 
therapy for HIV by activating this receptor. In this study, 
the detection of HIV restriction was not assessed, 
therefore, further research to detect and quantify RPRD2, 
SERINC3 and SERINC5 can be carried out to know if they 
are part of restriction factors that TLR3 activation can 
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upregulate. A possible advantage of this mechanism of 
therapy may be non-emergence of resistant strains that 
are associated with the current anti-retroviral therapy as 
TLR3 agonists will enhance the immune cells to curtail or 
inhibit the virus. This may offer a chance for a cure as a 
study has demonstrated the reversal of HIV latency in 
microglial cells following TLR3 receptor stimulation [17]. A 
recent clinical trial assessed poly I:C and poly-L-lysine 
(Poly ICLC) complex among 15 HIV positive adults that 
are on antiretroviral therapy. In addition to the  therapy 
being safe, it elicited immune responses that suggested 
the possible use of TLR3 as adjuvant among HIV patients 
[58]. More trials to understudy this is expected. 
The localisation of cellular proteins has influences on 
their functions and many transport systems are involved 
in nucleocytoplasmic trafficking [59, 60]. There are 
features of proteins that influence this, this includes the 
possession of NLS that is required for transportation of a 
protein into the nucleus. Importin α is important for this 
process and an example in humans is  KPNA2 (also 
called importin alpha 1) [59, 61]. In addition, post-
translational modification (PTM) of proteins is important 
in cellular pathways [51, 62]. A common example is 
ubiquitination and recently the addition of SUMO has 
been identified as another PTM that is important in the 
regulation of proteins [31, 33]. The traditional experiment 
to identify NLS and types of PTM is usually cumbersome 
and the development of computational methods to 
predict this has been useful [63]. In this study, NLS 
Mapper was used for predicting the NLS for the proteins 
with the cut-off set at 5.0. The range is from 2.0 to 10.0, 
the higher the score the higher the NLS activities. For 
example score of 8 to 9 and 1 to 2 means exclusive 
localisation to the nucleus and cytoplasm respectively 
[64]. At this cut-off, only RPRD2 showed NLS with a score 
of 9.8, table 1. This result implies an importin α shuttling 
of RPRD2 into the nucleus. SERINC3 and SERINC5 had 
NLS when the cut off was set at 2.0 but this was generally 
low giving credence to their cytoplasmic location, 
supplementary tables 5 and 6. It has been evidenced 
that HIV accessory protein capitalise on the intranuclear 
transport of restriction factors to initiate their 
degradation. Nuclear localisation of SAMHD1 has been 
shown to be required for Vpx-mediated ubiquitination 
and subsequent degradation. SAMHD1 was not 
degraded if localised to the cytoplasm [34, 35]. It was 
reported that intranuclear RPRD2 decreases in 
macrophages bearing Vpr accessory protein but 
increases if the virus lack Vpr. A decrease in RPRD2 was 
associated with higher susceptibility to HIV infection [65]. 
The cytoplasmic variants of the restriction factors were 
resistant to degradation mediated by the accessory 
proteins [34, 65]. Therefore, drugs that inhibit the nuclear 
transport of these restriction factors could be useful at 
ensuring their cytoplasmic presence to restrict HIV 
infection. 
 In the computational prediction of sumoylation and 
ubiquitination study, RPRD2 has a site for SUMO 
interaction and another for sumoylation consensus, 
figure 3a. The latter was statistically significant. The 
ubiquitination process is used for protein degradation 
among other functions and this mechanism of cellular 
protein disposal could be hijacked by HIV to degrade 
restriction factors [31]. RPRD2 has 44 residues of 
predicted lysine (K) ubiquitination with ten at high 
confidence, figure 2a. This implies a high chance of its 
being tagged with ubiquitin through a series of steps 
by the HIV accessory protein and causing its 
degradation [65]. A similar instance is a report that Vif  
induces the ubiquitination and subsequent 
degradation of APOBEC3G [31, 66, 67]. SERINC3 and 
SERINC55 had few predicted ubiquitination sites 
(SERINC5 has one with high confidence) as compared 
to RPRD2, figure 2.  The ubiquitination of SERINC5 was 
reported not to be mediated by Nef but in the 
presence of Nef, ubiquitinated SERINC5 colocalise 
with lysosome-associated membrane protein 1 (LAMP) 
for lysosomal degradation [68]. Protein sumoylation 
has been reported to cause modification that reduces 
the addition of ubiquitin and changes in 
conformation. Sumoylation is the covalent binding of 
SUMO to lysine reside while non-covalent interaction 
of proteins with SUMO or its chains is via SUMO-
interacting motifs (SIM) One of the effects of this is 
downregulation of ubiquitination system [49, 69, 70]. 
SERINC3 has six predicted SUMO interaction and two 
sumoylation non-consensus but none attain statistical 
significance, figure 3b, while the lone SUMO 
interaction seen in SERINC5 was statistically significant, 
figure 3c. The presence of significant SUMO interaction 
site in SERINC5 may be responsible for its higher 
potency than SERINC3. SERINC5 was shown to reduce 
HIV infection up to 90% while SERINC3 had 20% 
reduction in infection rate [32, 71, 72]. There were 
significant sumoylation consensus and almost 
statistically significant SUMO interaction in RPRD2, 
figure 3a. This may protect RPRD2 from Vpr-mediated 
ubiquitination and degradation. The knowledge of 
ubiquitination and sumoylation of SERINC3 and 
SERINC5 can be harnessed for therapeutic 
intervention of HIV. For stance, small molecules  that 
inhibit Vif  regulation of APOBECG3 and increasing its 
antiviral activities are in development [73, 74]. Study 
on the development of similar molecules that can 
potentiate the antiviral activities of RPRD2, SERINC3 
and SERINC5 based on the ubiquitination and 
sumoylation interactions could be developed as a 
novel HIV therapy. This may be combined with current 
antiretrovirals for synergy. It has been documented 
that SERINC5 increased the sensitivity to HIV 
neutralising antibodies and maraviroc [75]. 
In the study for the KPNA2 knockdown, the siRNA 
transfection procedure was not successful making 
KPNA2 bands to be present in the siRNA transfected 
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sample and the control. However, this was not surprising 
due to the low transfection efficiency of Jurkat cell line 
with Lipofectamine 3000 (<30%) [76]. Optimisation of the 
transfection process through modifications and trials 
may be undertaken towards increasing transfection 
efficiency. Replacing Jurkat cells in the experiment with 
other cell lines with higher transfection efficiency such 
as K-562 (human myelogenous leukemia, 30-50%) or 
MDA-MB-231 (human breast cancer, 51-79%) may be 
undertaken [76, 77]. However, this may not be ideal or 
economical. Optimisation of other reagents in the 
procedure can be done. The volume of Lipofectamine 
3000 reagent used in this study was 0.75 µl and 1.5 µl as 
stated in the manufacturer`s protocol. This can be 
scaled up to for example 2.5 µl or 5.0 µl in succession 
[78]. The concentration of siRNA is another factor that 
may determine the success of siRNA transfection. The 
range of concentrations recommended ranges from 5-
100 nM [79]. The concentration that was used in the 
study was 10 nm, another working concentration could 
be tried, a dose-response curve can be used to work 
out the optimal concentration for siRNA, but this will 
require large amount of siRNA. Therefore, titration of the 
siRNA amount with different concentrations can be 
tried [79, 80]. Another mechanism that can be used to 
improve transfection efficiency for siRNA is to tag it with 
fluorescent labels. This could help to identify cells that 
receive the siRNA and may be useful in correlating the 
transfection with the protein knockdown [80, 81]. The 
use of positive and negative controls has also been 
shown to help in the optimisation of transfection and in 
distinguishing non-specific effects of the siRNA 
respectively, for example siRNA GAPDH is commonly 
used for positive control [82, 83]. Transfection process 
could cause cellular toxicity and death, therefore 
assessing for cellular viability can be undertaken with 
the use of stain such as trypan blue to check for dead 
cells [80, 84]. It is expected that stepwise application of 
these optimisation alterations will lead to a successful 
KPNA2 knockdown and subsequent experiment such as 
localisation of RPRD2 to confirm its use since RPRD2 
possesses NLS with high score 
Limitations in this study include time constraint which 
precludes for example adequate optimisation for the 
KPNA2 knockdown. The laboratory for this study had a 
high number of other researchers sharing facilities at the 
same time (for example, the incubator  was frequently 
open and close), this may affect the optimal condition 
for the cultured cells and might have affected the 
results of the poly I:C treatment. 
 
Conclusion 
The need for the development of a new anti-HIV 
therapy is very crucial in other to address the present 
limitations of the available antiretrovirals. There has 
been a significant success with the current antiretrovirals 
but the loss of about a million lives to HIV every year is 
not acceptable. The knowledge of how the immune 
cells resist HIV infections via cellular restriction factors 
offers a potential therapeutic target. Researches on the 
characteristics of the immune restriction factors and the 
mechanism of how they interact with viral accessory 
proteins hold the key to the possibilities of developing 
drugs that utilises these proteins to inhibit HIV infections.  
While some restriction factors have been characterised, 
newer ones are being discovered and characterising 
them is an ongoing project. RPRD2, SERINC3 and 
SERINC5 are among the novel restriction factors. The 
activation of TLR3 has been showed to upregulate some 
restriction factors via interferon-mediated cellular 
signalling. It is yet to be determined if RPRD2, SERINC3 
and SERINC5 are part of the restrictions factors that are 
upregulated via this route. Studies to determine this is 
recommended. Report of a clinical trial that assessed 
the safety of a TLR3 agonist was satisfactory and it 
suggested the possible use of the drug as adjuvant to 
antiretrovirals. Similarly, the understanding of post-
translation modifications and how it alters the functions 
of HIV restriction factors can be harnessed as 
therapeutic targets. The development of small 
molecules that work through this mechanism such as 
preventing HIV accessory proteins degradation of 
restriction factors is being evaluated. It is anticipated 
that this may soon progress to the stage of clinical 
evaluation. The restriction factors may be able to 
address the problem of resistance associated with the 
antiretroviral drugs as their effects are exerted by 
increasing the capacity of the immune cells to ward off 
infection. This may also be one of the keys that will make 
HIV cure possible. More researches on characterising 
the novel HIV restriction factors are required and this 
may lead to a lethal addition to human armamentarium 
for the last battle that may end the war against HIV. 
 
References 
1. Bhatti AB, Usman M, Kandi V. Current Scenario of 
HIV/AIDS, Treatment Options, and Major Challenges 
with Compliance to Antiretroviral Therapy. Cureus. 
2016;8:e515. doi:10.7759/cureus.515. 
2. Daar ES. Novel approaches to HIV therapy. 
F1000Research. 2017;6:759. 
doi:10.12688/f1000research.11164.1. 
3. Elsheikh MM, Tang Y, Li D, Jiang G. Deep latency: 
A new insight into a functional HIV cure. 
EBioMedicine. 2019;45:624–9. 
doi:10.1016/j.ebiom.2019.06.020. 
4. WHO | HIV/AIDS. WHO. 2018. 
https://www.who.int/gho/hiv/en/. Accessed 5 Jun 
2019. 
10 
 
5. Spudich S, Robertson KR, Bosch RJ, Gandhi RT, 
Cyktor JC, Mar H, et al. Persistent HIV-infected cells 
in cerebrospinal fluid are associated with poorer 
neurocognitive performance. J Clin Invest. 
2019;129:3339–46. doi:10.1172/jci127413. 
6. Bruner KM, Cohn LB. HIV-1 reservoir dynamics in 
CD4+ T cells. Curr Opin HIV AIDS. 2019;14:108–14. 
doi:10.1097/COH.0000000000000521. 
7. Balasubramaniam M, Pandhare J, Dash C. 
Immune Control of HIV. J life Sci (Westlake Village, 
Calif). 2019;1:4–37. 
http://www.ncbi.nlm.nih.gov/pubmed/31468033. 
Accessed 26 Sep 2019. 
8. Gorin AM, Du Y, Liu FY, Zhang T-H, Ng HL, Hofmann 
C, et al. HIV-1 epitopes presented by MHC class I 
types associated with superior immune containment 
of viremia have highly constrained fitness 
landscapes. PLoS Pathog. 2017;13:e1006541. 
doi:10.1371/journal.ppat.1006541. 
9. D`Urbano V, De Crignis E, Re MC. Host Restriction 
Factors and Human Immunodeficiency Virus (HIV-1): 
A Dynamic Interplay Involving All Phases of the Viral 
Life Cycle. Curr HIV Res. 2018;16:184–207. 
doi:10.2174/1570162x16666180817115830. 
10. Colomer-Lluch M, Ruiz A, Moris A, Prado JG. 
Restriction Factors: From Intrinsic Viral Restriction to 
Shaping Cellular Immunity Against HIV-1. Frontiers in 
immunology. 2018;9:2876. 
doi:10.3389/fimmu.2018.02876. 
11. Jones CE, McKnight Á. Retroviral restriction: 
Nature’s own solution. Current Opinion in Infectious 
Diseases. 2016;29:609–14. 
doi:10.1097/QCO.0000000000000322. 
12. Mogensen TH. Pathogen recognition and 
inflammatory signaling in innate immune defenses. 
Clinical Microbiology Reviews. 2009;22:240–73. 
doi:10.1128/CMR.00046-08. 
13. Olive C. Pattern recognition receptors: sentinels 
in innate immunity and targets of new vaccine 
adjuvants. Expert Rev Vaccines. 2012;11:237–56. 
doi:10.1586/erv.11.189. 
14. Guo L, Xu X-Q, Zhou L, Zhou R-H, Wang X, Li J-L, et 
al. Human Intestinal Epithelial Cells Release Antiviral 
Factors That Inhibit HIV Infection of Macrophages. 
Front Immunol. 2018;9:247. 
doi:10.3389/fimmu.2018.00247. 
15. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 
Recognition of double-stranded RNA and activation 
of NF-κB by Toll-like receptor 3. Nature. 2001;413:732–
8. doi:10.1038/35099560. 
16. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, 
Chignard M, et al. Involvement of toll-like receptor 3 
in the immune response of lung epithelial cells to 
double-stranded RNA and influenza A virus. J Biol 
Chem. 2005;280:5571–80. 
doi:10.1074/jbc.M410592200. 
17. Alvarez-Carbonell D, Garcia-Mesa Y, Milne S, Das 
B, Dobrowolski C, Rojas R, et al. Toll-like receptor 3 
activation selectively reverses HIV latency in 
microglial cells. Retrovirology. 2017;14:9. 
doi:10.1186/s12977-017-0335-8. 
18. Xu X-Q, Guo L, Wang X, Liu Y, Liu H, Zhou R-H, et 
al. Human Cervical Epithelial Cells Release Antiviral 
Factors and Inhibit HIV Replication in Macrophages. 
J Innate Immun. 2019;11:29–40. 
doi:10.1159/000490586. 
19. Zhou Y, Wang X, Liu M, Hu Q, Song L, Ye L, et al. A 
critical function of toll-like receptor-3 in the induction 
of anti-human immunodeficiency virus activities in 
macrophages. Immunology. 2010;131:40–9. 
doi:10.1111/j.1365-2567.2010.03270.x. 
20. Sang M, Liu JB, Dai M, Wu JG, Ho WZ. Toll-like 
receptor 3 signaling inhibits simian 
immunodeficiency virus replication in macrophages 
from rhesus macaques. Antiviral Res. 2014;112:103–
12. doi:10.1016/j.antiviral.2014.10.008. 
21. Ramirez, Sharma, Singh, Stoneham, Vollbrecht, 
Guatelli. Plasma Membrane-Associated Restriction 
Factors and Their Counteraction by HIV-1 Accessory 
Proteins. Cells. 2019;8:1020. doi:10.3390/cells8091020. 
22. Zotova AA, Atemasova AA, Filatov A V., Mazurov 
D V. HIV Restriction Factors and Their Ambiguous 
Role during Infection. Mol Biol (Mosk). 2019;53:240–
55. doi:10.1134/S0026898419020174. 
23. Jáuregui P, Logue EC, Schultz ML, Fung S, Landau 
NR. Degradation of SAMHD1 by Vpx Is Independent 
of Uncoating. J Virol. 2015;89:5701–13. 
doi:10.1128/jvi.03575-14. 
24. Etienne L, Bibollet-Ruche F, Sudmant PH, Wu LI, 
Hahn BH, Emerman M. The Role of the Antiviral 
APOBEC3 Gene Family in Protecting Chimpanzees 
against Lentiviruses from Monkeys. PLoS Pathog. 
2015;11:e1005149. doi:10.1371/journal.ppat.1005149. 
25. Malim MH, Bieniasz PD. HIV restriction factors and 
mechanisms of evasion. Cold Spring Harb Perspect 
Med. 2012;2:a006940. 
doi:10.1101/cshperspect.a006940. 
26. Stremlau M, Song B, Javanbakht H, Perron M, 
Sodroski J. Cyclophilin A: An auxiliary but not 
necessary cofactor for TRIM5α restriction of HIV-1. 
Virology. 2006;351:112–20. 
doi:10.1016/j.virol.2006.03.015. 
27. Zhang F, Wilson SJ, Landford WC, Virgen B, 
Gregory D, Johnson MC, et al. Nef Proteins from 
Simian Immunodeficiency Viruses Are Tetherin 
Antagonists. Cell Host Microbe. 2009;6:54–67. 
doi:10.1016/j.chom.2009.05.008. 
28. Ghimire D, Rai M, Gaur R. Novel host restriction 
factors implicated in HIV-1 replication. Journal of 
11 
 
General Virology. 2018;99:435–46. 
doi:10.1099/jgv.0.001026. 
29. Marno KM, O’Sullivan E, Jones CE, Díaz-Delfín J, 
Pardieu C, Sloan RD, et al. RNA-Associated Early-
Stage Antiviral Factor Is a Major Component of Lv2 
Restriction. J Virol. 2017;91:e01228-16. 
doi:10.1128/jvi.01228-16. 
30. Usami Y, Wu Y, Göttlinger HG. SERINC3 and 
SERINC5 restrict HIV-1 infectivity and are 
counteracted by Nef. Nature. 2015;526:218–23. 
doi:10.1038/nature15400. 
31. Shao Q, Wang Y, Hildreth JEK, Liu B. 
Polyubiquitination of APOBEC3G Is Essential for Its 
Degradation by HIV-1 Vif. J Virol. 2010;84:4840–4. 
doi:10.1128/jvi.01911-09. 
32. Trautz B, Pierini V, Wombacher R, Stolp B, Chase 
AJ, Pizzato M, et al. The Antagonism of HIV-1 Nef to 
SERINC5 Particle Infectivity Restriction Involves the 
Counteraction of Virion-Associated Pools of the 
Restriction Factor. J Virol. 2016;90:10915–27. 
doi:10.1128/jvi.01246-16. 
33. Portilho DM, Fernandez J, Ringeard M, Machado 
AK, Boulay A, Mayer M, et al. Endogenous TRIM5α 
Function Is Regulated by SUMOylation and Nuclear 
Sequestration for Efficient Innate Sensing in Dendritic 
Cells. Cell Rep. 2016;14:355–69. 
doi:10.1016/j.celrep.2015.12.039. 
34. Brandariz-Nuñez A, Valle-Casuso JC, White TE, 
Laguette N, Benkirane M, Brojatsch J, et al. Role of 
SAMHD1 nuclear localization in restriction of HIV-1 
and SIVmac. Retrovirology. 2012;9:49. 
doi:10.1186/1742-4690-9-49. 
35. Schaller T, Pollpeter D, Apolonia L, Goujon C, 
Malim MH. Nuclear import of SAMHD1 is mediated 
by a classical karyopherin α/β1 dependent pathway 
and confers sensitivity to Vpx MAC induced 
ubiquitination and proteasomal degradation. 
Retrovirology. 2014;11:29. doi:10.1186/1742-4690-11-
29. 
36. Wang YJ, Wang X, Zhang H, Zhou L, Liu S, Kolson 
DL, et al. Expression and regulation of antiviral 
protein APOBEC3G in human neuronal cells. J 
Neuroimmunol. 2009;206:14–21. 
doi:10.1016/j.jneuroim.2008.10.003. 
37. Matsui M, Shindo K, Izumi T, Io K, Shinohara M, 
Komano J, et al. Small molecules that inhibit Vif-
induced degradation of APOBEC3G. Virol J. 
2014;11:122. doi:10.1186/1743-422X-11-122. 
38. Richardson MW, Guo L, Xin F, Yang X, Riley JL. 
Stabilized human TRIM5α protects human T cells from 
HIV-1 infection. Mol Ther. 2014;22:1084–95. 
doi:10.1038/mt.2014.52. 
39. Mi Z, Ding J, Zhang Q, Zhao J, Ma L, Yu H, et al. A 
small molecule compound IMB-LA inhibits HIV-1 
infection by preventing viral Vpu from antagonizing 
the host restriction factor BST-2. Sci Rep. 
2015;5:18499. doi:10.1038/srep18499. 
40. Weblet Importer. 
https://www.uniprot.org/uniprot/Q5VT52.fasta. 
Accessed 28 Sep 2019. 
41. Weblet Importer b. 
https://www.uniprot.org/uniprot/Q13530.fasta. 
Accessed 28 Sep 2019. 
42. Weblet Importer c. 
https://www.uniprot.org/uniprot/Q86VE9.fasta. 
Accessed 28 Sep 2019. 
43. NCBI. BLAST TOPICS. NCBI National Center for 
Biotechnology. 2002. 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&
PAGE_TYPE=BlastDocs&DOC_TYPE=BlastHelp. 
Accessed 30 Sep 2019. 
44. NLS Mapper. http://nls-
mapper.iab.keio.ac.jp/cgi-
bin/NLS_Mapper_form.cgi. Accessed 28 Sep 2019. 
45. UbPred: predictor of protein ubiquitination sites. 
http://www.ubpred.org/. Accessed 28 Sep 2019. 
46. GPS-SUMO: Prediction of SUMOylation Sites 
&amp; SUMO-interaction Motifs. 
http://sumosp.biocuckoo.org/online.php. Accessed 
28 Sep 2019. 
47. Zhao Q, Xie Y, Zheng Y, Jiang S, Liu W, Mu W, et 
al. GPS-SUMO: a tool for the prediction of 
sumoylation sites and SUMO-interaction motifs. 
Nucleic Acids Res. 2014;42 Web Server issue:W325-
30. doi:10.1093/nar/gku383. 
48. Radivojac P, Vacic V, Haynes C, Cocklin RR, 
Mohan A, Heyen JW, et al. Identification, analysis, 
and prediction of protein ubiquitination sites. 
Proteins. 2010;78:365–80. doi:10.1002/prot.22555. 
49. Pichler A, Knipscheer P, Oberhofer E, van Dijk WJ, 
Körner R, Olsen JV, et al. SUMO modification of the 
ubiquitin-conjugating enzyme E2-25K. Nat Struct Mol 
Biol. 2005;12:264–9. doi:10.1038/nsmb903. 
50. Lowrey AJ, Cramblet W, Bentz GL. Viral 
manipulation of the cellular sumoylation machinery. 
Cell Communication and Signaling. 2017;15:27. 
doi:10.1186/s12964-017-0183-0. 
51. Colomer-Lluch M, Castro-Gonzalez S, Serra-
Moreno R. Ubiquitination and SUMOylation in HIV 
Infection: Friends and Foes. Curr Issues Mol Biol. 
2019;35:159–94. doi:10.21775/cimb.035.159. 
52. Zhou Y, Guo M, Wang X, Li J, Wang Y, Ye L, et al. 
TLR3 activation efficiency by high or low molecular 
mass poly I:C. Innate Immun. 2013;19:184–92. 
doi:10.1177/1753425912459975. 
53. Salaun B, Coste I, Rissoan M-C, Lebecque SJ, 
Renno T. TLR3 Can Directly Trigger Apoptosis in 
Human Cancer Cells. J Immunol. 2006;176:4894–901. 
12 
 
doi:10.4049/jimmunol.176.8.4894. 
54. Palchetti S, Starace D, De Cesaris P, Filippini A, 
Ziparo E, Riccioli A. Transfected poly(I:C) activates 
different dsRNA receptors, leading to apoptosis or 
immunoadjuvant response in androgen-
independent prostate cancer cells. J Biol Chem. 
2015;290:5470–83. doi:10.1074/jbc.M114.601625. 
55. Salaun B, Lebecque S, Matikainen S, Rimoldi D, 
Romero P. Toll-like receptor 3 expressed by 
melanoma cells as a target for therapy? Clin 
Cancer Res. 2007;13:4565–74. doi:10.1158/1078-
0432.CCR-07-0274. 
56. Bou-Hanna C, Jarry A, Mosnier JF, Bossard C, 
Laboisse CL. The double stranded RNA analog poly-
IC elicits both robust IFN-λ production and oncolytic 
activity in human gastrointestinal cancer cells. 
Oncotarget. 2018;9:34471–84. 
doi:10.18632/oncotarget.26121. 
57. Li J, Wang Y, Wang X, Ye L, Zhou Y, Persidsky Y, et 
al. Immune activation of human brain microvascular 
endothelial cells inhibits HIV replication in 
macrophages. Blood. 2013;121:2934–42. 
doi:10.1182/blood-2012-08-450353. 
58. Saxena M, Sabado RL, Mar M La, Mohri H, 
Salazar AM, Dong H, et al. Poly-ICLC, a TLR3 agonist, 
induces transient innate immune responses in 
patients with treated HIV-infection: A randomized 
double-blinded placebo controlled trial. Front 
Immunol. 2019;10 APR:725. 
doi:10.3389/fimmu.2019.00725. 
59. Oka M, Yoneda Y. Importin α: functions as a 
nuclear transport factor and beyond. Proc Jpn 
Acad Ser B Phys Biol Sci. 2018;94:259–74. 
doi:10.2183/pjab.94.018. 
60. Goldfarb DS, Corbett AH, Mason DA, Harreman 
MT, Adam SA. Importin α: a multipurpose nuclear-
transport receptor. Trends Cell Biol. 2004;14:505–14. 
doi:10.1016/j.tcb.2004.07.016. 
61. Lange A, Mills RE, Lange CJ, Stewart M, Devine 
SE, Corbett AH. Classical nuclear localization signals: 
definition, function, and interaction with importin 
alpha. J Biol Chem. 2007;282:5101–5. 
doi:10.1074/jbc.R600026200. 
62. Rojas VK, Park I-W. Role of the Ubiquitin 
Proteasome System (UPS) in the HIV-1 Life Cycle. Int J 
Mol Sci. 2019;20. doi:10.3390/ijms20122984. 
63. He F, Wang R, Li J, Bao L, Xu D, Zhao X. Large-
scale prediction of protein ubiquitination sites using 
a multimodal deep architecture. BMC Syst Biol. 
2018;12 Suppl 6:109. doi:10.1186/s12918-018-0628-0. 
64. Kosugi S, Hasebe M, Tomita M, Yanagawa H. 
Systematic identification of cell cycle-dependent 
yeast nucleocytoplasmic shuttling proteins by 
prediction of composite motifs. Proc Natl Acad Sci U 
S A. 2009;106:10171–6. doi:10.1073/pnas.0900604106. 
65. Gibbons J, Marno K, Pike R, Lee J, Jones C, 
Ogunkolade W, et al. HIV-1 Vpr accessory protein 
interacts with REAF and mitigates its associated anti-
viral activity. Access Microbiol. 2019;1:408161. 
doi:10.1099/acmi.ac2019.po0083. 
66. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif 
protein binds the editing enzyme APOBEC3G and 
induces its degradation. Nat Med. 2003;9:1398–403. 
doi:10.1038/nm946. 
67. Iwatani Y, Chan DSB, Liu L, Yoshii H, Shibata J, 
Yamamoto N, et al. HIV-1 Vif-mediated 
ubiquitination/degradation of APOBEC3G involves 
four critical lysine residues in its C-terminal domain. 
Proc Natl Acad Sci U S A. 2009;106:19539–44. 
doi:10.1073/pnas.0906652106. 
68. Shi J, Xiong R, Zhou T, Su P, Zhang X, Qiu X, et al. 
HIV-1 Nef Antagonizes SERINC5 Restriction by 
Downregulation of SERINC5 via the 
Endosome/Lysosome System. J Virol. 2018;92:e00196-
18. doi:10.1128/JVI.00196-18. 
69. Colomer-Lluch M, Serra-Moreno R. 
BCA2/Rabring7 Interferes with HIV-1 Proviral 
Transcription by Enhancing the SUMOylation of IκBα. 
J Virol. 2017;91. doi:10.1128/JVI.02098-16. 
70. Cartier E, Garcia-Olivares J, Janezic E, Viana J, 
Moore M, Lin ML, et al. The SUMO-conjugase Ubc9 
prevents the degradation of the dopamine 
transporter, enhancing its cell surface level and 
dopamine uptake. Front Cell Neurosci. 2019;13:35. 
doi:10.3389/fncel.2019.00035. 
71. Rosa A, Chande A, Ziglio S, De Sanctis V, 
Bertorelli R, Goh SL, et al. HIV-1 Nef promotes 
infection by excluding SERINC5 from virion 
incorporation. Nature. 2015;526:212–7. 
doi:10.1038/nature15399. 
72. Zhang X, Zhou T, Yang J, Lin Y, Shi J, Zhang X, et 
al. Identification of SERINC5-001 as the Predominant 
Spliced Isoform for HIV-1 Restriction. J Virol. 2017;91. 
doi:10.1128/jvi.00137-17. 
73. Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra 
V, Rajendran KS, et al. Identification of a novel HIV-1 
inhibitor targeting Vif-dependent degradation of 
human APOBEC3G protein. J Biol Chem. 
2015;290:10504–17. doi:10.1074/jbc.M114.626903. 
74. Zuo T, Liu D, Lv W, Wang X, Wang J, Lv M, et al. 
Small-molecule inhibition of human 
immunodeficiency virus type 1 replication by 
targeting the interaction between Vif and ElonginC. 
J Virol. 2012;86:5497–507. doi:10.1128/JVI.06957-11. 
75. Beitari S, Ding S, Pan Q, Finzi A, Liang C. Effect of 
HIV-1 Env on SERINC5 Antagonism. J Virol. 2017;91. 
doi:10.1128/JVI.02214-16. 
76. ThermoFisher Scientific. Lipofectamine 3000 
Reagent - UK. 
https://www.thermofisher.com/uk/en/home/brands/
13 
 
product-brand/lipofectamine/lipofectamine-
3000.html. Accessed 27 Sep 2019. 
77. Song K-H, Jung S-Y, Park J-I, Ahn J, Park JK, Um H-
D, et al. Inhibition of Karyopherin-α2 Augments 
Radiation-Induced Cell Death by Perturbing BRCA1-
Mediated DNA Repair. Int J Mol Sci. 2019;20. 
doi:10.3390/ijms20112843. 
78. Lipofectamine 3000 Reagent Protocol. 
https://www.thermofisher.com/content/dam/LifeTe
ch/global/life-
sciences/CellCultureandTransfection/pdfs/Lipofecta
mine_3000_Protocol_6Dec2013.pdf?icid=cvc-
lipofectamine-c2m2. Accessed 29 Sep 2019. 
79. Proteintech. SiRNA: Overview and Technical Tips. 
https://www.ptglab.com/media/1516/knockdown-
slideshow.pdf. Accessed 29 Sep 2019. 
80. Abcam. Recommended checks and controls for 
siRNA experiments | Abcam. 
https://www.abcam.com/protocols/recommended
-checks-and-controls-for-sirna-experiments. 
Accessed 29 Sep 2019. 
81. Kasai H, Inoue K, Imamura K, Yuvienco C, 
Montclare JK, Yamano S. Efficient siRNA delivery and 
gene silencing using a lipopolypeptide hybrid vector 
mediated by a caveolae-mediated and 
temperature-dependent endocytic pathway. J 
Nanobiotechnology. 2019;17:11. doi:10.1186/s12951-
019-0444-8. 
82. Zagalak JA, Menzi M, Schmich F, Jahns H, Dogar 
AM, Wullschleger F, et al. Properties of short double-
stranded RNAs carrying randomized base pairs: 
Toward better controls for RNAi experiments. RNA. 
2015;21:2132–42. doi:10.1261/rna.053637.115. 
83. Lam JKW, Liang W, Lan Y, Chaudhuri P, Chow 
MYT, Witt K, et al. Effective endogenous gene 
silencing mediated by pH responsive peptides 
proceeds via multiple pathways. J Control Release. 
2012;158:293–303. doi:10.1016/j.jconrel.2011.11.024. 
84. Smith N, Vidalain PO, Nisole S, Herbeuval JP. An 
efficient method for gene silencing in human 
primary plasmacytoid dendritic cells: Silencing of the 
TLR7/IRF-7 pathway as a proof of concept. Sci Rep. 
2016;6. doi:10.1038/srep29891. 
   
